Q/C Technologies Inc
Research Q/C Technologies Inc (QCLS) on Bullrun: market cap USD 19.98M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQCLS
- ExchangeNASDAQ
- CountryUnited States
- SectorTechnology
- IndustryComputer Hardware
- CurrencyUSD
- Market capUSD 19.98M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.24M
- Free cash flow-USD 3.29M
Valuation Snapshot
latest market cap is USD 19.98M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.63M | -USD 10.82M | n/a | -8.66 | USD 987.00K | USD 0 | USD 21.75M |
| FY2024 | n/a | -USD 23.36M | n/a | n/a | -1080.87 | USD 173.15K | USD 10.58K | USD 9.79M |
| FY2023 | n/a | -USD 4.00M | n/a | n/a | -5.33 | USD 2.68M | n/a | USD 12.37M |
| FY2022 | n/a | -USD 15.20M | n/a | n/a | -11.74 | USD 749.09K | n/a | USD 14.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 19.98M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 30.68M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 13.21M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 45.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 229.07M | n/a | n/a | n/a |
About Q/C Technologies Inc
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease.
Related stock research
Other Technology stocks
Frequently asked questions
What is Q/C Technologies Inc's market cap?
Q/C Technologies Inc's market capitalization is USD 19.98M.
What does Q/C Technologies Inc do?
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression.